A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults

Trial Profile

A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jan 2017

At a glance

  • Drugs RVSV-S-GP/VP40 vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 09 Feb 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 09 Feb 2016 Change in Treatment table: A Placebo cohort has been added to treatments as per ClinicalTrials.gov record.
    • 02 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top